Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.
Mey UJ, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna CJ, Schmid M, Schmidt-Hieber M, Doerfel S, Fischer N, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Driessen C.
Mey UJ, et al. Among authors: pederiva s.
Br J Haematol. 2017 Mar;176(5):770-782. doi: 10.1111/bjh.14481. Epub 2016 Dec 16.
Br J Haematol. 2017.
PMID: 27983764
Free article.
Clinical Trial.